ReviewKidney international reports2024
Combination of Cardiovascular, Kidney, and Metabolic Diseases in a Syndrome Named Cardiovascular-Kidney-Metabolic, With New Risk Prediction Equations.
Review in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It reports registered trial NCT07465926. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Associations of Early Add-On GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy With Mortality and Kidney Outcomes in Adults With Obesity and Type 2 Diabetes Across Cardiovascular-Kidney-Metabolic Stages 2-3: A Target-Trial Emulation
Who cites it
48 citing papers in PubMed.
- Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial.Frontiers in endocrinology · 2026Trial
- Association of nephrolithiasis history with adverse outcomes in cardiovascular-kidney-metabolic syndrome.Renal failure · 2026Article
- Targeting the aldosterone-mineralocorticoid receptor pathway in cardiovascular-kidney-metabolic syndrome.Nature reviews. Nephrology · 2026Review
- Large-scale plasma proteomics improves prediction of heart failure among MASLD individuals: A prospective cohort study.American journal of preventive cardiology · 2026Article
- Joint Association of Functional Impairment and Depression with Advanced Cardiovascular-Kidney-Metabolic Syndrome: A Cross-Sectional and Cohort Study Using Two Large Datasets.Healthcare (Basel, Switzerland) · 2026Article
- A novel mouse model of adenine-supplemented high-fat diet induced cardiovascular-kidney-metabolic syndrome.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Age- and sex-specific normative values for reticulocyte indices and their relation to early-stage CKM syndrome.BMC cardiovascular disorders · 2026Article
- Food inflammation index and risks of all-cause and cardiovascular mortality among individuals with cardiovascular-kidney-metabolic syndrome: a nationally representative cohort study from NHANES 1999-2018.Scientific reports · 2026Article
- Optimal patient care in advanced chronic kidney disease progressing to kidney failure.Nature reviews. Nephrology · 2026Review
- Life's Essential 8-Defined Cardiovascular Health and Mortality Risk in Cardiovascular-Kidney-Metabolic Health Stages 0-4: A Cohort Study.Journal of epidemiology and global health · 2026Article
- Associations of frailty with the incidence and progression trajectory of cardiometabolic-kidney multimorbidity: insights from multi-state modelling.Journal of global health · 2026Article
- Cardiovascular-Kidney-Metabolic Syndrome and Life Expectancy in U.S. Adults.JACC. Advances · 2026Article
- Prognostic effect of estimated glucose disposal rate on all-cause and cardiovascular mortality among individuals cardiovascular-kidney-metabolic syndrome.Diabetology & metabolic syndrome · 2026Article
- Prevalence and Associated Factors of Renal Disease in Saudi Residents Attending Primary Health Care Centers in Riyadh, Saudi Arabia: Cross-Sectional Study.JMIR public health and surveillance · 2026Article
- Cardiometabolic index and cardiovascular disease incidence in middle-aged and older Chinese: A nationwide prospective cohort study.Medicine · 2026Observational
- The Relationship Between Dietary Inflammatory Index and Intermediate-to-High-Risk Cardiovascular-Kidney-Metabolic Syndrome and All-Cause Mortality: The National Health and Nutrition Examination Survey 1999-2018: A Cross-Sectional and Prospective Cohort Study.Health science reports · 2026Article
- Bridging Innovation and Practice in Type 2 Diabetes Mellitus: Novel Antidiabetic Therapies and the Expanding Role of Community Pharmacists.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Comment on Yuan et al. Associations of Concurrent Hypertension and Type 2 Diabetes With Mortality Outcomes: A Prospective Study of U.S. Adults: Diabetes Care 2025;48:1241-1250.Diabetes care · 2026Article
- Associations between cardiovascular-kidney-metabolic syndrome staging and risks of all-cause and cardiovascular mortality: a systematic review and meta-analysis.American journal of preventive cardiology · 2026Article
- Metabolic Dysfunction at the Core: Revisiting the Overlap of Cardiovascular, Renal, Hepatic, and Endocrine Disorders.Life (Basel, Switzerland) · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Associations of chronic kidney disease (CKD) with metabolic syndrome and cardiovascular disease (CVD) have long been recognized. Until recently, such associations were mainly limited to interrelationships between either heart and kidney, heart and metabolic syndrome, or metabolic syndrome and kidney. It is the merit of the American Heart Association (AHA) to have set up a work group of cardiologists, endocrinologists, and nephrologists for the purpose of combining all 3 disorders in a single entity, as an appreciation of their pathophysiological interrelatedness. To this end, they proposed the term cardiovascular-kidney-metabolic (CKM) syndrome, which reflects multidirectional relationships among metabolic risk factors, CKD, and the cardiovascular system. Following a consensus approach in defining CKM with 5 stages, the work group subsequently developed new risk prediction equations, named predicting risk of CVD events (PREVENT) equations, which included estimated glomerular filtration rate (eGFR) and albuminuria as variables in addition to traditional cardiovascular and metabolic factors. Despite several limitations, this development is a major step forward in cardiovascular risk prediction. Its clinical application should translate into earlier, more appropriate treatment and prevention of CKM syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.